Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.82 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351632 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2PTGDR | |
| SCHEMBL4090073 | 0.85 | PTGER4 (0.76) | PTGER4PTGER2PTGDR | |
| SCHEMBL5361496 | 0.83 | PTGER4 (0.66) | PTGER4PTGER2PTGDR | |
| SCHEMBL14301885 | 0.83 | PTGER4 (0.82) | PTGER4PTGER2PTGDR | |
| SCHEMBL4085019 | 0.83 | PTGER4 (0.82) | PTGER4PTGER2PTGDR | |
| SCHEMBL4302915 | 0.82 | PTGER4 (0.55) | PTGER4 | |
| SCHEMBL2355901 | 0.81 | PTGER4 (1.00) | PTGER4PTGER2PTGDR | |
| SCHEMBL14299039 | 0.81 | PTGER4 (1.00) | PTGER4PTGER2PTGDR | |
| SCHEMBL2356121 | 0.81 | PTGER4 (1.00) | PTGER4PTGER2PTGDR | |
| SCHEMBL13649260 | 0.80 | PTGER4 (0.82) | PTGER4PTGER2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| EP-2054401-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | Merck Frosst Canada Ltd. (CA) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PTGDR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.